DE60317606T2 - Marker für Brustkrebsprognose - Google Patents

Marker für Brustkrebsprognose Download PDF

Info

Publication number
DE60317606T2
DE60317606T2 DE60317606T DE60317606T DE60317606T2 DE 60317606 T2 DE60317606 T2 DE 60317606T2 DE 60317606 T DE60317606 T DE 60317606T DE 60317606 T DE60317606 T DE 60317606T DE 60317606 T2 DE60317606 T2 DE 60317606T2
Authority
DE
Germany
Prior art keywords
seq
genes
portfolio
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60317606T
Other languages
German (de)
English (en)
Other versions
DE60317606D1 (de
Inventor
Yixin San Diego Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Clinical Diagnostics Inc
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60317606(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of DE60317606D1 publication Critical patent/DE60317606D1/de
Application granted granted Critical
Publication of DE60317606T2 publication Critical patent/DE60317606T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE60317606T 2002-03-29 2003-03-31 Marker für Brustkrebsprognose Expired - Fee Related DE60317606T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36878902P 2002-03-29 2002-03-29
US368789P 2002-03-29

Publications (2)

Publication Number Publication Date
DE60317606D1 DE60317606D1 (de) 2008-01-03
DE60317606T2 true DE60317606T2 (de) 2008-10-23

Family

ID=29215884

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60317606T Expired - Fee Related DE60317606T2 (de) 2002-03-29 2003-03-31 Marker für Brustkrebsprognose

Country Status (11)

Country Link
US (1) US7473526B2 (enExample)
EP (1) EP1367138B1 (enExample)
JP (1) JP2003325192A (enExample)
KR (1) KR20030078805A (enExample)
CN (1) CN1495274A (enExample)
AR (1) AR039213A1 (enExample)
AU (1) AU2003203557B2 (enExample)
BR (1) BR0303092A (enExample)
CA (1) CA2422303A1 (enExample)
DE (1) DE60317606T2 (enExample)
MX (1) MXPA03002864A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
JP5089993B2 (ja) * 2004-02-20 2012-12-05 ベリデックス・エルエルシー 乳癌の予後診断
JP2007532142A (ja) * 2004-04-23 2007-11-15 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がん遺伝子発現バイオマーカー
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
EP2380978A3 (en) * 2006-02-03 2012-02-29 MessengerScape Co. Ltd. Gene group applicable to cancer prognostication
BRPI0720219A2 (pt) 2006-12-08 2013-12-24 Univ Iowa State Res Found Inc Genes de planta envolvidos em absorção e metabolismo de nitrato
CN105224827B (zh) * 2008-07-01 2019-12-24 小利兰·斯坦福大学托管委员会 用于发展ivf治疗协议的分析数据的计算机系统和存储介质
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
US10011876B2 (en) 2010-11-23 2018-07-03 Krisani Biosciences Pvt. Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US635152A (en) * 1899-06-05 1899-10-17 Melancthon S Shotwell Car-body bolster.
US6350576B1 (en) 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
AU5310296A (en) 1995-03-17 1996-10-08 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
US6275814B1 (en) 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6037129A (en) 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
US6175624B1 (en) * 1999-03-05 2001-01-16 Centurion International, Inc. Method for connecting a battery circuit in a cellular telephone
MXPA01009369A (es) 1999-03-15 2003-06-06 Eos Biotechnology Inc Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal.
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
US6175824B1 (en) 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
RU2251838C2 (ru) 1999-07-15 2005-05-20 Рисерч Дивелопмент Фаундейшн Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
US20050054826A1 (en) * 2003-05-19 2005-03-10 Rosetta Inpharmatics Llc Human diaphanous-3 gene and methods of use therefor

Also Published As

Publication number Publication date
CA2422303A1 (en) 2003-09-29
AU2003203557B2 (en) 2007-05-24
DE60317606D1 (de) 2008-01-03
BR0303092A (pt) 2004-09-08
KR20030078805A (ko) 2003-10-08
EP1367138A2 (en) 2003-12-03
US20030190656A1 (en) 2003-10-09
US7473526B2 (en) 2009-01-06
JP2003325192A (ja) 2003-11-18
AU2003203557A1 (en) 2003-10-23
AR039213A1 (es) 2005-02-09
EP1367138A3 (en) 2004-03-10
CN1495274A (zh) 2004-05-12
MXPA03002864A (es) 2004-08-11
EP1367138B1 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
US7348142B2 (en) Cancer diagnostic panel
US20230287511A1 (en) Neuroendocrine tumors
US20100009371A1 (en) Selection of markers
Fridman et al. Accurate molecular classification of renal tumors using microRNA expression
DE60317606T2 (de) Marker für Brustkrebsprognose
AT505726A2 (de) Set von tumor-markern
Goldsmith et al. The microrevolution: applications and impacts of microarray technology on molecular biology and medicine
DE69929785T2 (de) Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs
EP2092087B1 (de) Prognostische marker für die klassifizierung von kolorektalen karzinomen basierend auf expressionsprofilen von biologischen proben
US20170183738A1 (en) Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers
DE102010043541A1 (de) Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
DE112018006190T5 (de) Subtypisierung von tnbc und methoden
US20050287541A1 (en) Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma
EP1683862A1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
DE602004005650T2 (de) Verfahren zur klassifizierung der genexpressionsstärke in lungenkrebsgeweben
EP2092085B1 (de) Prognostische marker für die klassifizierung des dreijährigen progressionsfreien überlebens von patienten mit kolorektalem karzinom basierend auf expressionsprofilen von biologischen proben
EP2092086B1 (de) Prognostische marker für dievorhersage des fünfjährigen progressionsfreien überlebens von patienten mit kolorektalen karzinomen basierend auf expressionsprofilen von biologischen proben
Kim et al. Factors for risk stratification of patients with actinic keratosis using integrated analysis of clinicopathological features and gene expression patterns
DE102017125013A1 (de) MCC als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere basophiler Granulozyten
BE1030423B1 (de) Anwendung von Biomarkern zu Diagnose und Behandlung von pulmonaler Hypertonie (PH)
KR102101872B1 (ko) 폐 노화 판별용 바이오마커 조성물 및 이의 용도
Marquardt Machine-Learning-Based Identification of Tumor Entities, Tumor Subgroups, and Therapy Options
Yang et al. Low‐grade BRAF V600E mutant oligodendroglioma‐like tumors of children may show EGFR and MET amplification
DE10326773B4 (de) Detektieren des wiederaufgetretenen und im fortgeschrittenen Stadium befindlichen Blasenkarzinoms
CN115472294A (zh) 预测小细胞转化肺腺癌患者转化速度的模型及其构建方法

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee